These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 15328187)

  • 1. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
    Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
    Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of medulloblastoma in children under age of three years.
    Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
    Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
    Aldosari N; Bigner SH; Burger PC; Becker L; Kepner JL; Friedman HS; McLendon RE
    Arch Pathol Lab Med; 2002 May; 126(5):540-4. PubMed ID: 11958658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior.
    McManamy CS; Pears J; Weston CL; Hanzely Z; Ironside JW; Taylor RE; Grundy RG; Clifford SC; Ellison DW;
    Brain Pathol; 2007 Apr; 17(2):151-64. PubMed ID: 17388946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
    Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
    J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.
    Eberhart CG; Kratz JE; Schuster A; Goldthwaite P; Cohen KJ; Perlman EJ; Burger PC
    Brain Pathol; 2002 Jan; 12(1):36-44. PubMed ID: 11770900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
    Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
    J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas.
    McManamy CS; Lamont JM; Taylor RE; Cole M; Pearson AD; Clifford SC; Ellison DW;
    J Neuropathol Exp Neurol; 2003 Jun; 62(6):627-32. PubMed ID: 12834107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.
    Brown HG; Kepner JL; Perlman EJ; Friedman HS; Strother DR; Duffner PK; Kun LE; Goldthwaite PT; Burger PC
    J Neuropathol Exp Neurol; 2000 Oct; 59(10):857-65. PubMed ID: 11079775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas.
    Schofield D; West DC; Anthony DC; Marshal R; Sklar J
    Am J Pathol; 1995 Feb; 146(2):472-80. PubMed ID: 7856756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
    DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
    Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.